Finding broadly protective antibodies against Crimean-Congo Hemorrhagic Fever
Official title: Isolation of broadly protective monoclonal antibodies for Crimean Congo Hemorrhagic Fever
Funded at University of Maryland Baltimore · NIH-11556149 · Data updated 2026-11-12
Researchers will study blood from people who survived CCHF to find human antibodies that protect against multiple virus variants, with early tests in animal models to check their breadth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 23, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $58,536 |
| NIH project number | 3R01AI180125-03S1 |
| Project ID | NIH-11556149 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who have survived Crimean-Congo Hemorrhagic Fever and have usable blood samples for antibody isolation.
✕Less likely to help
People without prior CCHF infection or without access to survivor samples may not directly benefit.
What this research studies
CCHF is a serious tick-borne illness with no approved vaccine or specific treatment. The project will build a cohort of CCHF survivors, isolate up to 75 anti-CCHFV antibodies from their blood, and select nine promising antibodies for further testing. These antibodies will be evaluated for their ability to provide cross-protection against different virus variants in a lethal mouse model, and the researchers will map where these antibodies bind on the virus. By understanding which antibodies are broadly protective, this work aims to guide future therapies or vaccines for CCHF.
Why it matters
Potential benefit: If successful, patients could one day benefit from antibody-based therapies or vaccines that protect against multiple strains of CCHFV.
How similar studies have gone: Previous work showed protective antibodies in mice and humans, with this study aiming to broaden breadth across virus variants.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
Related research
Other NIH-funded projects on the same topics.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
A New Model for Valley Fever: Studying Coccidioides Infection with Volatile Clues in Wax Moths
Researchers are testing a new, cheaper model using wax moths to study Valley Fever caused by Coccidioides, with the goal of understanding how the infection behaves and how it could be diagnosed or treated.
-
Halogen-modified nucleoside analogs to fight yellow fever virus
Aims to develop new oral medicines that could prevent or treat yellow fever by using specially modified building blocks that stop the virus from growing.
-
Understanding Guanarito virus and building countermeasures for Venezuelan hemorrhagic fever
This project studies how Guanarito virus causes disease and aims to develop vaccines or treatments to protect people in areas where Venezuelan hemorrhagic fever occurs.
-
Fever-related heat and disturbed blood flow weaken the artery lining via a cellular stress pathway
This study will explore how fever-range heat and uneven blood flow together harm the inner lining of arteries, especially in areas prone to atherosclerosis, by triggering a specific cellular stress pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.